effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects

OBJECTIVE: To investigate whether weekly subcutaneous administration of 60 mg of long-acting pegylated human leptin (PEG-OB) for 8 weeks was able to influence weight loss, metabolic profile and inflammatory status of obese subjects on a mildly hypoenergetic diet (deficit: 3.2 MJ/day). DESIGN: A pros...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Obesity 2002-04, Vol.26 (4), p.504-509
Main Authors: Hukshorn, C.J, Dielen, F.M.H. van, Buurman, W.A, Westerterp-Plantenga, M.S, Campfield, L.A, Saris, W.H.M
Format: Article
Language:English
Subjects:
Analysis. Health state
Biological and medical sciences
Body mass index
C-reactive protein
Cytokines
Diet
Drug dosages
Epidemiology
General aspects
humans
leptin
Lipids
low calorie diet
Medical sciences
men
Metabolic diseases
Metabolism
Nutrition research
Obesity
Proteins
Public health. Hygiene
Public health. Hygiene-occupational medicine
subcutaneous injection
Substance abuse treatment
Tumor necrosis factor-TNF
tumor necrosis factors
Weight control
weight loss
women
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE: To investigate whether weekly subcutaneous administration of 60 mg of long-acting pegylated human leptin (PEG-OB) for 8 weeks was able to influence weight loss, metabolic profile and inflammatory status of obese subjects on a mildly hypoenergetic diet (deficit: 3.2 MJ/day). DESIGN: A prospective, randomized, double-blind and placebo-controlled single-center trial. SUBJECTS: Twenty-eight healthy, obese subjects (16 women, 12 men; age 22-65 y; body mass index 27.7-38.7 kg/m2). MEASUREMENTS: Bodyweight, metabolic profile (including lipids), C-reactive protein (CRP) and soluble TNF α-receptor (sTNF-R) 55 and 75 levels. RESULTS: At the end of the study no significant differences in the delta or percentage weight loss between the placebo (n=14) and PEG-OB (n=14) groups was observed. Also the changes in metabolic profile, CRP, sTNF-R55 and R75 concentrations between the two groups after 8 weeks of treatment did not differ. CONCLUSION: Weekly injection of 60 mg PEG-OB did not lead to additional weight loss after 8 weeks of treatment. Furthermore, PEG-OB administration did not affect the changes in metabolic profile and the inflammatory status of obese subjects.
ISSN:0307-0565
1476-5497
DOI:10.1038/sj.ijo.0801952